• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量异烟肼在耐多药结核病患儿中的药代动力学。

Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.

机构信息

Desmond Tutu TB Centre, Department of Paediatrics, Stellenbosch University, Cape Town, South Africa.

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

出版信息

Int J Tuberc Lung Dis. 2021 Nov 1;25(11):896-902. doi: 10.5588/ijtld.20.0870.

DOI:10.5588/ijtld.20.0870
PMID:34686231
Abstract

High-dose isoniazid (INH) (15-20 mg/kg/day) could be administered to overcome low-level INH resistance, but pharmacokinetic data are sparse. This observational study included South African children (<15 years) receiving INH as preventive therapy, or treatment for multidrug-resistant TB (MDR-TB) exposure or disease. Pharmacokinetic sampling was performed after an INH dose of 20 mg/kg. Non-compartmental analysis and multivariable regression models were used to evaluate associations of key covariates with area under the curve (AUC) and maximum concentration (C). AUC and C values were compared against proposed adult targets. Seventy-seven children were included, with median age of 3.7 years; 51 (66%) had MDR-TB disease and 26 (34%) had MDR-TB exposure. Five were HIV-positive, of whom four were ≥5 years old. The median AUC was 19.46 µgh/mL (IQR 10.76-50.06) and C was 5.14 µg/mL (IQR 2.69-13.2). In multivariable analysis of children aged <5 years, MDR-TB disease (vs. exposure) was associated with considerably lower AUC (geometric mean ratio GMR 0.19, 95% CI 0.15-0.26; < 0.001) and C (GMR 0.20, 95% CI 0.15-0.26; < 0.001). INH concentrations in children with MDR-TB disease were much lower than expected, but comparable to previous reports in children with MDR-TB exposure. Further studies should confirm these findings and explore possible causes.

摘要

高剂量异烟肼(INH)(15-20 毫克/千克/天)可用于克服低水平 INH 耐药,但药代动力学数据很少。本观察性研究纳入了南非接受 INH 预防治疗或治疗耐多药结核(MDR-TB)暴露或疾病的儿童(<15 岁)。在给予 20 毫克/千克 INH 剂量后进行药代动力学采样。采用非房室分析和多变量回归模型评估关键协变量与曲线下面积(AUC)和最大浓度(C)的相关性。AUC 和 C 值与成人目标值进行了比较。共纳入 77 例儿童,中位年龄为 3.7 岁;51 例(66%)患有 MDR-TB 疾病,26 例(34%)患有 MDR-TB 暴露。5 例 HIV 阳性,其中 4 例年龄≥5 岁。AUC 中位数为 19.46µgh/mL(IQR 10.76-50.06),C 中位数为 5.14µg/mL(IQR 2.69-13.2)。在<5 岁儿童的多变量分析中,MDR-TB 疾病(与暴露相比)与 AUC 显著降低相关(几何均数比 GMR 0.19,95%CI 0.15-0.26;<0.001)和 C(GMR 0.20,95%CI 0.15-0.26;<0.001)。患有 MDR-TB 疾病的儿童的 INH 浓度远低于预期,但与之前报道的患有 MDR-TB 暴露的儿童相似。进一步的研究应证实这些发现并探讨可能的原因。

相似文献

1
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.高剂量异烟肼在耐多药结核病患儿中的药代动力学。
Int J Tuberc Lung Dis. 2021 Nov 1;25(11):896-902. doi: 10.5588/ijtld.20.0870.
2
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.高剂量异烟肼治疗印度尼西亚利福平或耐多药结核病的药代动力学和药效学。
J Antimicrob Chemother. 2024 May 2;79(5):977-986. doi: 10.1093/jac/dkae057.
3
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.儿童耐多药结核病的治疗和结局:系统评价和个体患者数据荟萃分析。
PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.
4
Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.南非自由州省与耐多药结核病相关的异烟肼耐药突变体的流行情况。
S Afr Med J. 2019 Aug 28;109(9):659-664. doi: 10.7196/SAMJ.2019.v109i9.13730.
5
Prevalence and factors associated with multidrug-resistant tuberculosis in South India.印度南部耐多药结核病的流行情况及相关因素。
Sci Rep. 2020 Oct 16;10(1):17552. doi: 10.1038/s41598-020-74432-y.
6
Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.印度采用间歇疗法治疗的合并结核病的HIV感染儿童中一线抗结核药物的药代动力学
Antimicrob Agents Chemother. 2015 Feb;59(2):1162-7. doi: 10.1128/AAC.04338-14. Epub 2014 Dec 8.
7
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.洛匹那韦利托那韦与一线和二线抗结核药物在治疗耐多药结核病的 HIV 感染儿童中的药代动力学和药物相互作用。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.00420-17. Print 2018 Feb.
8
Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.异烟肼和吡嗪酰胺在儿童中的药代动力学研究:年龄和营养状况的影响。
Arch Dis Child. 2018 Dec;103(12):1150-1154. doi: 10.1136/archdischild-2017-313910. Epub 2018 Mar 7.
9
Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.氧氟沙星在耐药性肺结核儿童中的药代动力学及安全性
Antimicrob Agents Chemother. 2015 Oct;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.
10
Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.莫西沙星在耐多药儿童肺结核患者中的药代动力学及安全性
Clin Infect Dis. 2015 Feb 15;60(4):549-56. doi: 10.1093/cid/ciu868. Epub 2014 Oct 30.

引用本文的文献

1
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.高剂量异烟肼治疗印度尼西亚利福平或耐多药结核病的药代动力学和药效学。
J Antimicrob Chemother. 2024 May 2;79(5):977-986. doi: 10.1093/jac/dkae057.
2
Current Treatment of Drug-Resistant Tuberculosis in Children.儿童耐多药结核病的治疗现状。
Indian J Pediatr. 2024 Aug;91(8):806-816. doi: 10.1007/s12098-023-04888-z. Epub 2023 Nov 23.
3
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
标准剂量与高剂量异烟肼治疗耐多药结核病的药代动力学。
J Antimicrob Chemother. 2022 Aug 25;77(9):2489-2499. doi: 10.1093/jac/dkac188.
4
Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?高剂量是否足以使耐多药结核病患儿达到较高的异烟肼暴露水平?
Int J Tuberc Lung Dis. 2021 Nov 1;25(11):879-880. doi: 10.5588/ijtld.21.0451.